Shattuck Labs, INC Form 4 insider transactions

Shattuck Labs Chief Technical Officer Abhinav Shukla executed a series of transactions involving company stock and stock options, primarily under a pre-established Rule 10b5-1 trading plan.

Abhinav A. Shukla, Chief Technical Officer at Shattuck Labs, Inc., reported transactions involving the acquisition and sale of company common stock on June 30 and July 1, 2026, executed under a Rule 10b5-1 trading plan.

Shattuck Labs Chief Medical Officer, Arundathy N. Pandite, sold 30,000 shares of common stock for approximately $7.01 per share under a pre-established Rule 10b5-1 trading plan.

Director Mona Ashiya reports the acquisition of pre-funded warrants by OrbiMed-affiliated entities following a public offering.

OrbiMed Advisors acquired over 1.25 million pre-funded warrants in Shattuck Labs' recent public offering.

Director Clay B. Siegall purchased 62,500 shares of Shattuck Labs, Inc. common stock as part of a recent underwritten offering.

OrbiMed Advisors exercised common warrants for pre-funded warrants in Shattuck Labs, Inc. on June 8, 2026.

Director Mona Ashiya reports the exercise of common warrants into pre-funded warrants for Shattuck Labs, Inc. (STTK).

Director Daniel G. Baker was granted options to purchase 81,000 shares of Shattuck Labs common stock.

Director George Golumbeski was granted 81,000 stock options in Shattuck Labs, Inc. as part of standard equity compensation.

Director Neil W. Gibson was granted 81,000 stock options in Shattuck Labs, Inc. as part of an equity compensation arrangement.

Director Mona Ashiya was granted 81,000 stock options in Shattuck Labs, Inc. with an exercise price of $5.95.

Director Clay B. Siegall was granted 81,000 stock options in Shattuck Labs, Inc. as part of a standard equity compensation arrangement.

Director Helen M. Boudreau was granted 81,000 stock options in Shattuck Labs, Inc. as part of standard equity compensation.

Shattuck Labs Director Clay B. Siegall reports transactions involving the acquisition of common stock and accompanying warrants through a private placement.

Shattuck Labs Chief Technical Officer Abhinav A. Shukla acquired company stock and warrants through a private placement.

Shattuck Labs reports insider Stephen Stout acquired 12,805 shares of common stock and accompanying warrants in a private placement.

Shattuck Labs CFO Andrew R. Neill exercised warrants to acquire 64,027 shares of common stock at a price of $1.0846 per share.

Chief Technical Officer Abhinav A. Shukla exercised options and sold shares under a pre-established Rule 10b5-1 trading plan.

Chief Medical Officer Arundathy N. Pandite sold 30,000 shares of Shattuck Labs common stock via a Rule 10b5-1 trading plan.

Shattuck Labs CEO Taylor Schreiber acquired 25,610 shares of common stock and accompanying warrants in a private placement.

General Counsel Stephen Stout reported the disposition of 968 shares of Shattuck Labs common stock to cover tax obligations.

Shattuck Labs' Chief Medical Officer, Arundathy N. Pandite, disposed of 3,195 shares of common stock for tax withholding purposes.

Stephen Stout, General Counsel of Shattuck Labs, reported the disposition of 593 common shares to cover tax withholding on January 25, 2026.

Shattuck Labs' Chief Business Officer, Casi DeYoung, disposed of 2,286 shares of common stock to cover tax withholding obligations at a price of $4.15 per share.

Shattuck Labs CFO Andrew R. Neill disposed of 2,589 common shares at $4.15 each to cover tax liabilities, retaining 228,224 shares.

Shattuck Labs' General Counsel Stephen Stout reported the acquisition of 351,400 stock options and the disposition of 4,153 common shares on January 10, 2026.

Shattuck Labs' CBO, Casi DeYoung, reported a grant of 381,600 stock options and a tax-related sale of 5,699 shares.

Shattuck Labs' Chief Technical Officer, Abhinav A. Shukla, was granted options to purchase 315,500 shares of common stock at an exercise price of $4.75 per share.

Shattuck Labs' Chief Medical Officer, Arundathy N. Pandite, was granted 487,800 stock options and simultaneously disposed of 6,851 shares of common stock to cover tax obligations.